Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study.

Slides:



Advertisements
Similar presentations
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples by Pilar Hernandez,
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,
Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Future Strategies for Myeloma
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front- line therapy with novel agents combinations  Aurelio Lopez, Maria-Victoria.
How I treat extramedullary myeloma
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
How I treat multiple myeloma in younger patients
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.
Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their.
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.
Transplants for the elderly in myeloma
How I treat elderly patients with myeloma
An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
Nonmyeloablative conditioning for relapsed follicular lymphoma
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.
The role of complete response in multiple myeloma
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma 
by Alexander Röth, Andreas Hüttmann, Russell P
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Paul G. Richardson, Wanling.
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Stage C or not stage C…? by Claire Dearden Blood
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,
Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma 
Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.
BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent.
On the Cusp: New Approaches for Multiple Myeloma
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab.
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab- Treated Patients With Relapsed or Refractory Multiple Myeloma  Ajai Chari,
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study by Shaji Kumar, Ravi Vij, Jonathan L.
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Treatment options for relapsed and refractory multiple myeloma
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma.
Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.
Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study by Radhakrishnan Ramchandren,
Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary.
Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term.
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL.
Cold agglutinin disease
Presentation transcript:

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study by Sagar Lonial, Jesus F. San-Miguel, Joaquín Martínez-Lopez, Maria-Victoria Mateos, Joan Blade, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Ajai Chari, Luis Pineiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan Schecter, and Philippe Moreau Blood Volume 130(Suppl 1):1869-1869 December 7, 2017 ©2017 by American Society of Hematology

Sagar Lonial et al. Blood 2017;130:1869 ©2017 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.